For the first time in history, a small group of people suffering from rectal cancer have passed a clinical trial, leaving everyone with tears of joy. Accordingly New York Times, 18 patients took a drug called Dostarlimab for about six months and the result shocked everyone. It was noted that patients underwent a series of medical tests including physical examination, endoscopy, bioscopy, PET scan and MRI scan and there was no identifiable cancer. After six months of treatment, the patients recovered completely.Also read – Explained the early warning signs of cancer; Blinking in the body can also be a major warning sign
Which medicine was used to cure cancer?
According to reports, Dostarlimab is a drug with laboratory-produced molecules that act as substitute antibodies in the human body. All 18 patients with rectal cancer were given the same drug and the cancer was completely eradicated in each patient due to the treatment – cannot be detected by physical examination; Endoscopy; Positron emission tomography or PET scan or MRI scan. Also read – Feeling of trembling in the body? Watch out for these early symptoms of cancer
In general, cancer patients undergo difficult and painful treatments, including surgery, chemotherapy and radiation. In rare cases, patients with rectal cancer also undergo bowel, urinary, and erectile dysfunction. Also read – Today’s horoscope: Cancer, Scorpio births windfall benefits for expecting romantic traps
The latest trends seem to be a blessing in disguise for those seeking cancer treatment. Although the sample size of the trial is small, the trial proved that it can cure painful cancer. Dr. of Memorial Sloan Catering Cancer Center in New York. Lewis A. “This is the first time this has happened in the history of cancer,” said Diaz J.A.
Patients were found to have taken the drug every three weeks for six months. According to reports, the patients were all in the same stage of their cancer. The cancer spread locally to the rectum but did not spread to other organs.
The results certainly look promising, however, large-scale trials should be conducted.
This has been published in the study New England Journal of Medicine. The study is supported by drugmaker GlaxoSmithKline.
